Om oss

Cessatech A/S (“Cessatech” or the “Company”) is a clinical Phase II company developing evidence-based treatment for children. The lead asset (CT001) is an analgesic nasal spray for acute and planned painful procedures treatments in children. The advantages include needle-free administration, being easy to administer, a fast-acting therapeutic effect and being medically approved for children.